Leptin (116-130), amide, mouse: Molecular Insights and Translational Impact

Introduction: Beyond Metabolism—A New Era for Leptin Fragments

Leptin (116-130), amide, mouse, has emerged as a central experimental tool in the study of metabolic disease, immunity, and tissue remodeling. As a biologically active peptide fragment derived from the adipocyte-derived hormone leptin, this molecule encapsulates the core sequence (Ser-Cys-Ser-Leu-Pro-Gln-Thr-Ser-Gly-Leu-Gln-Lys-Pro-Glu-Ser-NH2) responsible for much of leptin’s canonical and noncanonical signaling. While prior literature has focused on its applications in obesity and diabetes models, the Leptin (116-130), amide, mouse fragment now stands at the intersection of metabolic regulation, immunology, and cardiovascular research, offering unique opportunities for translational science.

Mechanism of Action: Dissecting the Core Bioactivity

The biological effects of native leptin are mediated through its interaction with the leptin receptor (Ob-R), influencing pathways that govern appetite, energy expenditure, and neuroendocrine function. Leptin (116-130), amide, mouse is a synthetic fragment that retains the critical receptor-binding region, enabling it to mimic native hormone activity while allowing for more targeted experimental designs. This peptide’s solubility profile—insoluble in ethanol but highly soluble in DMSO (≥156 mg/mL) and water (≥24.15 mg/mL)—facilitates its use across diverse assay systems, from cell culture to in vivo models.

Upon administration, the 116-130 sequence efficiently recapitulates leptin’s downstream signaling, including JAK/STAT, PI3K/Akt, and MAPK pathways, all of which are vital for energy homeostasis regulation and immune modulation. Its pleiotropic effects extend to hematopoiesis, angiogenesis, blood pressure control, bone mass maintenance, and lymphoid homeostasis, positioning it as a versatile research tool for metabolic and immunological studies.

Integrating Evidence: The SIRT6-AMPK Pathway as a Translational Bridge

Recent advances in cardiovascular and metabolic disease models have underscored the importance of metabolic-immune crosstalk. A landmark study investigating the role of the SIRT6-AMPK axis in atrial fibrillation (AF) pathogenesis revealed that SIRT6-AMPK signaling is a critical modulator of inflammasome activation, fibrosis, and tissue vulnerability. Berberine, a small molecule, was shown to inhibit the NLRP3 inflammasome by upregulating SIRT6-AMPK, thus protecting against angiotensin II-induced atrial remodeling and AF susceptibility.

While the study focused on berberine, the mechanistic insight into SIRT6-AMPK signaling is highly relevant for leptin research. Leptin fragments, including the 116-130 sequence, are known to interface with AMPK and inflammatory cascades, suggesting that the Leptin (116-130), amide, mouse fragment could serve as a mechanistic probe for dissecting these pathways in both metabolic and cardiovascular disease contexts.

Reference Insight Extraction: Why SIRT6-AMPK Matters for Leptin Fragment Assays

The reference study’s most meaningful innovation lies in establishing SIRT6-AMPK as a nodal point connecting metabolic signaling, inflammation, and tissue remodeling. For researchers utilizing leptin fragments, this means:

• Assay Design: Experiments can be constructed to interrogate how leptin (and its fragments) modulate SIRT6 or AMPK activity, particularly in models of insulin resistance, obesity, or cardiac fibrosis.
• Translational Value: The overlap between leptin signaling and SIRT6-AMPK opens avenues for investigating combinatorial interventions targeting both metabolic and inflammatory pathways.
• Protocol Optimization: Given the crosstalk between these axes, the timing, dosing, and cellular context of leptin fragment application should be carefully considered, especially in models where inflammasome activation or tissue remodeling is relevant.

This mechanistic clarity aids practical assay decisions by pinpointing endpoints (e.g., AMPK phosphorylation, NLRP3 activation) that reflect both metabolic and immunologic outcomes.

Comparative Analysis: Distinctive Features of Leptin (116-130), amide, mouse

Compared to full-length leptin, the 116-130 fragment offers several advantages for experimental design:

• Specificity: The fragment allows for the isolation of core receptor-mediated effects, reducing off-target or confounding hormonal influences.
• Solubility and Stability: Its robust solubility in water and DMSO ensures compatibility with a range of protocols, while solid storage at -20°C enhances long-term stability.
• Pleiotropic Reach: Beyond classical metabolic endpoints, this fragment can be leveraged to study hematopoiesis, vascular biology, and immune function.

While existing articles such as "Mechanism, Application, Vision" provide an overview of leptin signaling and translational models, the present work distinguishes itself by deeply integrating recent findings in the SIRT6-AMPK axis and their ramifications for protocol development and cross-domain research.

Advanced Applications: From Obesity to Cardiovascular-Immune Models

The utility of Leptin (116-130), amide, mouse, now extends far beyond obesity and diabetes research. Its ability to modulate energy homeostasis regulation and immune pathways makes it invaluable for:

• Metabolic-Cardiovascular Studies: By probing the intersection of leptin signaling and the SIRT6-AMPK pathway, researchers can model the metabolic contributions to cardiac fibrosis, arrhythmogenesis, and vascular remodeling.
• Immunometabolic Research: The fragment’s pleiotropic effects allow for the dissection of immune cell energetics, lymphoid organ homeostasis, and T-cell function under metabolic stress.
• Infertility and Bone Homeostasis: Applications in reproductive biology and bone mass regulation are supported by leptin’s broader physiological roles, as described in the product information.

This perspective is distinct from the protocol-centric focus of "Protocols for Obesity Research", which emphasizes assay workflows, and from the practical troubleshooting orientation of "Reliable Assays for Obesity Research". Here, the emphasis is on cross-system integration and translational hypothesis generation.

Protocol Parameters

• Concentration for in vitro studies: Typically 10–1000 nM, titrated according to cell type and experimental endpoint.
• Solvent preparation: Dissolve in DMSO or water to achieve ≥24.15 mg/mL (water) or ≥156 mg/mL (DMSO), as indicated in the APExBIO product specification. Avoid ethanol, as the peptide is insoluble.
• Storage conditions: Store as a desiccated solid at -20°C. Prepare fresh solutions before use; avoid long-term storage of reconstituted peptide.
• Timing considerations: For studies investigating acute versus chronic signaling (e.g., AMPK activation vs. long-term fibrosis), adjust treatment durations accordingly—ranging from 30 minutes (acute phosphorylation) to several days (remodeling endpoints).
• Controls: Include vehicle-only and/or full-length leptin controls to contextualize fragment-specific effects.

Why This Cross-Domain Matters, Maturity, and Limitations

The integration of metabolic, immune, and cardiovascular research is rapidly maturing, driven by discoveries like the SIRT6-AMPK axis’s role in inflammasome regulation. For leptin fragment studies, this cross-domain approach is crucial for unraveling the complex etiology of multifactorial diseases such as metabolic syndrome, heart failure, and autoimmune conditions. However, the translational maturity is still emerging; while preclinical evidence supports these mechanistic links, clinical validation and standardized protocols remain works in progress. Researchers should interpret results with an awareness of model-specific nuances and the need for longitudinal studies.

Conclusion and Future Outlook

Leptin (116-130), amide, mouse, is more than a peptide fragment—it is a gateway to advanced mechanistic and translational research at the intersection of metabolism, immunity, and cardiovascular biology. By leveraging insights from the SIRT6-AMPK signaling pathway and optimizing experimental protocols, scientists can illuminate new therapeutic strategies for complex diseases. Continued advances in assay design, molecular targeting, and cross-domain integration will further enhance the value of this APExBIO reagent in preclinical research. For a deeper exploration of signaling pathway nuances and future directions in metabolic disease models, readers may consult "Beyond Obesity—Molecular Pathways and Research Frontiers", which complements the present article by mapping emergent frontiers in the field.